The week that went by saw NASH drug stocks back in focus as positive results from a phase II study of Galmed Pharmaceuticals Ltd.'s (GLMD) investigational drug Aramchol seems to have had a positive rub off impact. Aramchol is being developed for treatment of patients with biopsy proven non-alcoholic steatohepatitis, or NASH.
from RTT - Biotech https://ift.tt/2JZtQDV
via IFTTT
No comments:
Post a Comment